The report ‘Non-Alcoholic Steatohepatitis (NASH/MASH): Epidemiology Forecast to 2032’ predicts the US to have the highest NASH cases in 2032 at 10.45 million, while Spain is estimated to have the lowest at 1.15 million within the 7MM.
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), represents a progressive liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage. This condition can advance to more severe stages, leading to fibrosis, cirrhosis, and even liver failure in some cases.
Metabolic-associated fatty liver disease (MAFLD), formerly known as alcoholic fatty liver disease, encompasses a broader spectrum of liver conditions linked to metabolic dysfunction, encompassing similar characteristics as NASH. Both NASH and MAFLD are strongly associated with obesity, insulin resistance, type 2 diabetes, and other metabolic factors, making them prevalent concerns in the context of modern lifestyles.
Advertisement
Casey Freimuth, Senior Epidemiologist at GlobalData, emphasizes the need to monitor trends in NAFLD, obesity, and type 2 diabetes for predicting NASH’s future burden. Surveillance of risk factors like waist circumference, body mass index, triglycerides, and gamma-glutamyl Transferase levels is deemed vital in assessing NASH risk within populations.
Early NASH diagnosis becomes critical, as cirrhosis lacks a curative treatment. Effective management targeting obesity and insulin resistance, the underlying causes, is pivotal in preventing liver failure.
Reference :
- Diagnosed prevalent cases of NASH to reach 26.55 million – (https://www.globaldata.com/media/pharma/diagnosed-prevalent-cases-nash-reach-26-55-million-7mm-2032-estimates-globaldata/)
Source: Medindia
